Chronic pulmonary aspergillosis (CPA) is slowly progressive inflammatory pulmonary syndrome due to Aspergillus spp. The evidence regarding CPA treatment is limited. We conducted a randomized, multicenter, open-label trial comparing intravenous micafungin (MCFG) of 150-300 mg once daily with intravenous voriconazole (VRCZ) of 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily for the treatment of 107 inpatients with CPA to compare the efficacy and safety of both drugs as initial treatment in Japan. 
INTRODUCTION
Chronic forms of pulmonary aspergillosis (CPA) are characterized as a slowly progressive inflammatory pulmonary syndrome due to Aspergillus spp. 1, 2 Several names of these chronic forms of disease have been proposed: semi-invasive aspergillosis 3 , chronic necrotizing pulmonary aspergillosis (CNPA) 4 , simple or complex aspergilloma, and chronic cavitary and fibrosing pulmonary aspergillosis (CCPA and CFPA). 5 As Hope et al. 6 indicated apparently distinct entities do not exist for this syndrome and these forms usually overlap. The common characteristics of these forms, however, consist of 1)
underlying pulmonary disorders, 2) the status of low-grade immunosuppression, and 3)
less than severe findings of angioinvasion in histopathology. 1, 5, 7 Numerous clinical cases and few retrospective studies have been reported for the treatment of CPA [8] [9] [10] [11] [12] ; however, there are no large-scale clinical trials have been conducted.
Although the latest Infectious Diseases Society of America (IDSA) guidelines for the treatment of aspergillosis recommend oral azoles for CPA as primary treatment 13 , the utility of antifungal injections for CPA treatment is not known. Intravenous antifungal agents may possess important role as an induction therapy followed by oral antifungal drugs as maintenance therapy for CPA cases. Several kinds of intravenous antifungal agents active to Aspergillus spp. are available. Micafungin (MCFG) is new semisynthetic lipopeptide antifungal drug in the echinocandin family that has been developed in Japan. 14 Several in vitro and in vivo studies have shown high levels of antifungal activity against Aspergillus spp. [15] [16] [17] Voriconazole (VRCZ), from a newer generation of triazoles, has also potent anti-aspergillus activity in vivo and in vitro. 18, 19 Our study is the first prospective large-scale trial comparing intravenous MCFG and intravenous VRCZ as induction therapy in CPA patients who require immediate treatment.
METHODS

Patients
From April 1, 2006 , to November 30, 2008, we enrolled patients with CPA at 24
Japanese hospitals in this study, which was approved by the ethics committee at each hospital. Every patient provided written informed consent. Astellas, Co. Ltd. (Tokyo, Japan) supported the study with a grant; Astellas, Co. Ltd. was not involved in the design of study, the enrollment of patients, the collection, analysis, interpretation of the data or preparation of the manuscript. All authors vouch for the completeness and accuracy of the data presented.
Patients were eligible for enrollment if they were at least 20 years old and had been given a diagnosis of CPA. The diagnostic criteria of Hope et al. for CPA including chronic CNPA, CCPA, CFPA and complex aspergilloma were used in this study. 6 Proposed enrollment criteria for prospective clinical studies of CPA by Denning with minor modifications were used for this trial.
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Patients with CPA had to fulfill the following conditions: (1) the existence of at least one of the symptoms in the complex consisting of fever, weight loss, sputum, cough, hemoptysis, fatigue, and shortness of breath; (2) 
Procedures
The patients were allocated to either the MCFG or VRCZ treatment group. The randomization of the minimization method was performed at a centralized web site by attending physicians after obtaining the informed consent from each patient. Random numbers were generated by the computer. Stratification factors of severity and past history of treatment of CPA including aspergilloma were used. Severity was defined as mild, moderate and severe. The factors that were used for determining severity were (1) serum albumin value (less than 2.5 g/dl), (2) SpO 2 less than 90% or PaO 2 less than 60 Torr, (3) impaired oral administration of drugs, (4) expansion of newer infiltration shadow on chest X-ray film that was more than half of the lung field, (5) the existence of severe complications such as malignancies, cerebral vascular disorders, hepatic diseases, kidney diseases or heart failure, and (6) administration of corticosteroids. Mild severity was defined as the patient possessing none of the above factors. Moderate severity was defined as the patient possessing only one of the factors listed above. Severe severity was defined as the patient possessing at least two of the factors listed above. The randomization schedule was generated by a computer to ensure balanced treatment allocation. Briefly, when the difference of number of allocated patients between the MCFG and VRCZ groups was less than two, the patients were completely randomized. Hence, when the difference was more than three, the patients were allocated to the smaller number therapy group at 90% probability or the bigger number therapy group at 10% probability.
VRCZ was given intravenously at 6 mg/kg every 12 h for 24 h, and then 4 mg/kg every 12 h. MCFG was given at 150-300 mg per day. Dose of MCFG was accepted to be decreased due to patient's body weight by the decision of the attending physician. The reason that the dose of MCFG was not fixed in this study was that no data was available about the dose effect of MCFG in the treatment of pulmonary aspergillosis. Patients received treatment for at least 2 weeks with a maximum duration of 4 weeks.
Patients were followed up until 4 weeks after the first administration. Clinical assessments were made daily during treatment. Clinical laboratory tests were run once every week. Radiological and mycological investigations were performed at 2 weeks and at the end of treatment with a maximum 4 weeks. Concurrent treatment with antibiotics was prohibited in this study.
The primary efficacy end point was response to treatment, which was classified as 'success' or 'failure' at the end of administration (at least 2 weeks of administration with a maximum duration of 4 weeks). Each case was carefully reviewed by the investigators. All clinical response criteria were defined as previously reported with slight modifications. 8 Briefly, four groups of factors, consisting of (1) The secondary efficacy end point was response to treatment, which was classified as 'success' or 'failure' at the end of 2 weeks administration. All four groups of factors were used as in the primary endpoint; however, the criterion of "success" was changed as follows: improvement in at least one of the four groups of factors without deterioration in other groups of factors.
Adverse events were recorded from randomization until the last day of treatment. These events were classified according to the Common Toxicity Criteria grading system of the National Cancer Institute.
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Statistical analysis
The primary objective was to show the superiority of each drug in the per-protocol population. Because number of CPA patients, data for the efficacy of antifungals to CPA and budget were limited, the sample size for this clinical trial was set on the basis of the frequency of adverse events of both drugs. On the basis of the rate of adverse events, which averaged 35% for MCFG and 62% for VRCZ, a power of 0.80 and the requirement to show the superiority of one drug to the comparator group with a significance of 5.0%
for the final analysis were set. A total sample size of 100 patients (50 assigned MCFG and 50 assigned VRCZ) satisfying the criteria for the per-protocol population was calculated to be necessary.
The intention-to-treat population was defined as patients who underwent randomization.
The modified intention-to-treat population was defined as patients who received at least one dose of the study drug they were initially assigned to receive and who had a baseline diagnosis of CPA. The per-protocol population was defined as patients who were confirmed to have a baseline diagnosis of CPA, the availability of an investigator's assessment of over all treatment at the end of therapy, at least 14 doses of one of the study drugs, and no prohibited medication. The population included in the safety analysis consisted of all patients who received their initial study drug. The investigator's assessments of overall treatment success at the end of therapy and at the end of the first 2 weeks were analyzed with a two-sided 95% confidence intervals (CI). Non-inferiority of MCFG could be concluded if the two-sided 95% CI for the difference in the proportions (MCFG minus VRCZ) had a lower boundary above -15%. Categorical variables were tested by the Fisher's exact test and were expressed as frequencies and proportions.
Continuous variables were tested by the Student's t-test and were expressed as means and ranges. A P-value of <0.05 was considered statistically significant.
RESULTS
Enrollment and baseline characteristics of the patients
A total of 107 patients were recruited by 24 centers in Japan during study period. A total of 53 and 54 patients were assigned to the MCFG and VRCZ group, respectively; these patients comprised the intention-to-treat population. Trial profile was presented in Figure   1 . All 107 patients were recruited for safety analysis. Four and six patients were excluded from the intention-to-treat population and the modified intention-to-treat population, respectively. One case in the VRCZ-treated group lacked the assessment data at the first 2 weeks of treatment; therefore, this case was not evaluated at the secondary endpoint but was evaluated at the primary endpoint. The demographic characteristics and underlying conditions of the patients in the intention-to-treat population are summarized in Table 1 .
The MCFG and VRCZ groups were well matched and no significance difference was observed in the intention-to-treat and modified intention-to-treat populations (data not shown).
Base-line characteristics of the infection and the serological findings
Characteristics of the patients with CPA such as symptoms, signs, and inflammation markers and the results of the serum tests prior to the administration of study drugs in the per-protocol populations are summarized in Table 2 . There were no significant differences in the clinical characteristics including symptoms, laboratory findings and the serological test result between the MCFG and VRCZ groups.
The results of the culture test and biopsy of respiratory specimens are shown in Table 3 .
The positive rate of culture tests remained at only 50%.
Response
The Table 4 . There was no significant difference in the response rates among all factors between the MCFG and VRCZ groups.
The outcome at the end of the first 2 weeks of treatment was not significantly different between the MCFG and the VRCZ group. In the intention-to-treat population, success rates were 64.2% (34 of 53 patients) with MCFG and 50.0% (27 of 54 patients) with VRCZ (absolute difference, 14.2%; 95% CI, -4.61 to 32.91). The response rates of the four groups of evaluated factors were not significantly different (Table 4 ).
Because the lower 95%confidence limit for the difference between MCFG and VRCZ at both endpoints settings was below zero, MCFG was considered to be neither inferior nor superior to VRCZ. Table 5 shows the treatment-related adverse events and reasons for discontinuation from the study in patients who received at least one dose of study drug. Significantly fewer adverse effects were observed in the MCFG group than in the VRCZ group. Hepatic events were the most frequent adverse events in both the MCFG and VRCZ groups (8 cases in the MCFG group and 15 cases in the VRCZ group). There were four cases in which VRCZ was discontinued due to severe hepatic events (at least one of the values of glutamic oxaloacetic transamidase, glutamic pyruvic transamidase, alkaline phosphatase, or gamma-glutamyl transpeptidase exceeded 2.5 times the value of the upper normal limit).
Safety
Various visual events including photophobia, xanthopsia, abnormal vision, defective color vision, vision blurred, and visual disturbance occurred only in the VRCZ group and all visual events were transient and resolved without intervention. All of the adverse effects other than visual events recovered during the treatment or after the end of treatment, except in one case with alkaline phosphatase elevation, which was mild.
DISCUSSION
In the current study, we recruited patients who basically satisfied the criteria for the clinical study of CPA proposed by Denning et al. 5 The inclusion criteria in this study were designed to recruit patients who required immediate treatment. Another consideration was made using broad-spectrum antibiotics prior to registration to minimize registering patients with bacterial infections in addition to aspergillosis.
The latest IDSA guidelines for the treatment of aspergillosis recommend oral VRCZ or ITCZ for CPA as primary treatment The overall effective rate of both drugs however, was only around 60% with average duration periods about 3 weeks. The response rates of evaluation factors after the first 2 weeks and at the end of treatment indicated that longer treatment will increase the response rate of all factors with almost 10% of improve rate gained except Aspergillus eradication. There were four cases in which a high dose of MCFG (300 mg/day) was used in this study. Three of four patients were successfully treated and there were no major adverse reactions. However, this data is not showing dose effect of MCFG, the population of patients taking a high dose of MCFG is too small to compare the dose effect of MCFG in patients with CPA.
Our results indicated apparently fewer adverse effects in the MCFG than VRCZ group, even though the average administration period was longer by 3 days. The incidence rate of adverse events was still significantly lower in MCFG group even with exclusion of visual events, which are unique to VRCZ. VRCZ is metabolized via the cytochrome P450 (CYP)
2C19 isozyme in liver 21 and the CYP2C19 mutant type is generally found in 60% -70%
of Asian populations including Japanese, 22 which indicates that these poor metabolizers of VRCZ are likely to have more serious liver dysfunction. Our current data showed significantly more occurrence of liver dysfunction in the VRCZ than MCFG group.
Although the MCFG group showed a lower incidence rate of adverse effects, one case with disseminated intravascular coagulation (DIC) was reported as a severe adverse effect.
DIC occurred 4 days after the discontinuation of MCFG in this case and the patient recovered. Monitoring blood concentration of VRCZ, not performed in current study, might support further understanding of frequency and severity of adverse effects.
Our study also revealed the important clinical aspects of patients with CPA in Japan.
The mean age of the patients with CPA was 70.9 years old and most patients were men with malnutrition and pulmonary complications, especially tuberculosis sequelae. Smith et al. showed that tuberculosis sequelae are also a major risk factor in patients with CPA in United Kingdom 23 . Only the Aspergillus antibody test by the Aspergillus immunodiffusion system showed a reasonably high positive rate with 88.6% of all patients, which resembled the previous results by Denning et al. 2, 5 The common serum antigen detecting tools for invasive Aspergillus infection are not suitable for CPA diagnosis. Renal events 1 (1.9 %) Renal events 1 (1.9 %)
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